The Klein Donation: Text of Robert Klein’s Comments on Special Treatment by CIRM
By Dr. Matthew Watson
Here is the text of comments from
Robert Klein, former chairman of the California stem cell agency,
concerning his $21,630 donation to the agency and subsequent actions
by the agency. Klein's comments May 1 came in response to questions
from the California Stem Cell Report(CSCR) on April 30. The text of
the inquiry from CSCR precedes Klein's response. Here is a link to the story on the matter.
"I have sent the following to CIRM
asking for their response and am offering the same opportunity to
you. Here is what I sent the agency:
'The documents that I have received so
far show that after Klein gave CIRM $21,000 the agency instructed six
of its science officers to give him special access to their
activities and apparently did not object to additional instructions
from another member of the public, Melissa King, to provide Klein and
her with written summaries about their activities at the ISSCR
convention and “details” about their work at CIRM. Email
addresses of the six were also provided to Klein, who may have
additionally received their cell phone numbers although that is not
entirely clear. The CIRM documents show that the six were told to
engage in one-on-one sessions with Klein, which actually included a
third person, a wealthy Canadian mining company executive. One
document indicates that the science officers should assist in
fundraising for CIRM by identifying areas of “special importance”
to Klein and 'other donors.'
"'Additionally, Alan Trounson, at
Klein's request, invited the mining executive to a closed door
session involving the agency's international partners, a session at
which presumably valuable, little known scientific information would
be discussed and future directions charted. Trounson specifically
told the executive that it was Klein who asked that executive be
invited to the session, adding to Klein's clout in any business or
other dealings that Klein might have with the executive.'
My questions to CIRM deal with the
special treatment that was provided in connection with your donation.
I would ask you if you think that state agencies should provide this
sort of extraordinary treatment for individuals who donate to the
agency. At the very least, doesn't this raise questions about the
integrity of the agency and doubts in the public mind about whether
it can be fair and even-handed in its activities?
"In April or May of 2012 I committed
to contribute a charitable donation to CIRM to cover the travel costs
for 5-7 additional science officers to attend the International Stem
Cell Conference in Japan. It is important to CIRM that their
science officers understand the cutting edge research being developed
around the world so that CIRM does not fund redundant research; but,
to the contrary, the science officers understand how to create
networks between California scientists and scientists in other
foreign countries who are doing complementary research that can
potentially accelerate the advancements of therapies for patients. I
do not hold any financial interest in biotech companies. I have
historically been involved in encouraging international collaboration
to advance medical therapies; for patients, every day of delay in the
development of a therapy is a delay they cannot afford. To
conceptually document the value of additional scientists traveling to
these meetings, it was discussed that there should be conceptual,
bullet point summaries about the value for CIRM obtained through the
scientists discussions at the international conference. The
idea was to create bullet points of information about a few of the
most meaningful scientific concepts and contacts the science officers
benefitted from each day of attendance at the conference. I did not
participate in the selection of the science officers who attended and
I did not play any part in determining what activities they
participated in. There were two fundamental goals to the very short
one-on-one sessions that were arranged at "down time" that
would not conflict with their other activities. The first goal was to
conceptually understand if each of the science officers believed that
the benefit to the agency was sufficient to justify the cost of their
attending, when considering the learning and contacts they had gained
which might accelerate research and therapies for patients. The
second goal was to assist universities and non-profits, principally
in Canada - a research partner of CIRM - in advancing their
contributions from an existing donor or donors."The Canadian mining executive had an
important history in contributing to the International Stem Cell
Society and to Canadian non-profit research institutions. This
individual has an expert background in mining and a passionate
personal commitment to medical research; but, he does not engage in
technical discussions of research. On a conceptual basis it was
important for him to understand the spectrum of medical advances
towards therapies. His additional contributions to Canadian
non-profits could assist Canada in collaborating with California on
more international research, with California only funding the
research done in California and the donor helping to fund the
research done in Canada. No specific grant applications were
discussed. Finally, the discussion with the international partners
focuses on the funding process and funding collaboration it does not
discuss any individual grants. The value of international
collaboration and the benefits of collaborating with new
international partners is discussed. Scientific theories and
individual grants are not discussed and new scientific information is
not presented. I attended this session of international partners to
support international collaboration; again, I do not hold any
financial interest in any biotech organizations. Additionally, I do
not have any business or financial relationship with the Canadian
mining executive. The Canadian executive, based upon family and
friends who have had chronic disease, is a significant donor to
non-profit research institutions in Canada. All of my activities, the
donation and the encouragement to develop information to validate the
future benefits of science officers traveling to international stem
cell conferences were focused on benefitting California patients with
chronic illness or injury and the agency formed through Proposition
71."
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/SBGFem2qPWo/the-klein-donation-text-of-robert.html
- 001 International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- 002 CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- 003 International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- 004 MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- 005 CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- 006 Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- 008 International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- 009 CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- 010 International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 011 Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- 012 US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- 013 International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- 014 An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- 015 International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- 016 Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- 017 CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- 018 International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- 019 International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- 020 Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- 021 New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- 022 Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- 023 OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- 024 International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- 025 International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 026 California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 027 International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- 028 Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- 029 International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- 030 Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- 031 Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 032 More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- 033 International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- 034 Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- 035 Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- 036 Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- 037 International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 038 Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 039 Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- 040 International Stem Cell Corporation - Breakthrough Technology Alert [Last Updated On: August 6th, 2010] [Originally Added On: August 6th, 2010]
- 041 Oxygen, hypoxia and the stem cell niche [Last Updated On: August 7th, 2010] [Originally Added On: August 7th, 2010]
- 042 Partnership Pays Off [Last Updated On: August 17th, 2010] [Originally Added On: August 17th, 2010]
- 043 Video: Summary of Recent Developments in Stem Cell and Regenerative Medicine from Kenneth Aldrich, Chairman of International Stem Cell Corporation [Last Updated On: August 18th, 2010] [Originally Added On: August 18th, 2010]
- 044 International Stem Cell Corporation Formalizes Stem Cell Based Eye Care Programs into Cytovis™ [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 045 International Stem cell Corporation Chairman Discusses Recent Stem Cell Research Funding Decision [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 046 International Stem Cell Corporation Not Adversely Affected by Stem Cell Research Funding Ban [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 047 A Primer on the Use of Stem Cells in Ophthalmology by Irving J. Arons [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 048 Kenneth Aldrich, Chairman and Co-Founder of International Stem Cell Corporation will be making two public appearances this week on behalf of ISCO. [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 049 International Stem Cell Corporation Reports Significant Progress Towards Creation of the First Bank of Immune-Matched Human Parthenogenetic Stem Cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 050 International Stem Cell Corporation and Insight Bioventures India Structure Indian Affiliate to Develop Stem Cell-Based Eye Care Therapeutics... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 051 ISCO to Present Data on Progress of Human Parthenogenetic Stem Cell Differentiation into Functional Liver Cells at the Annual Meeting... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 052 Putative tumor-initiating progenitor cells predict poor lung cancer prognosis [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 053 Therapeutic implications of colon CSCs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 054 Selective targeting of neuroblastoma tumour-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 055 Two Open Access reviews [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 056 Isolation and killing of candidate CML stem cells by antibody targeting [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 057 Some breast cancer tumors may not originate from stem cells? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 058 On the low frequency of tumor-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 059 Must the last CML cell be killed? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 060 Critical molecular pathways in CSCs of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 061 Insights into the stem cells of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 062 International Stem Cell Corporation Announces Launch Plans for New Skin Care Products [Last Updated On: October 16th, 2010] [Originally Added On: October 16th, 2010]
- 063 International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care's Stem Cell-Based Skin Rejuvenation... [Last Updated On: October 26th, 2010] [Originally Added On: October 26th, 2010]
- 064 Notes from The Chairman Concerning ISCO Price Fluctuations [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 065 Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation's (ISCO) Therapeutic Research [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 066 International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 067 International Stem Cell Corporation Announces Commercial Sales to General Public of Its Breakthrough Stem Cell-Based Lines of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 068 International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement [Last Updated On: December 15th, 2010] [Originally Added On: December 15th, 2010]
- 069 International Stem Cell Corporation Announces Start of Marketing Collaboration with John Mauldin for Skin Care Products [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 070 International Stem Cell Corporation to Present Ethical and Technical Qualities of Human Parthenogenetic Stem Cells at the Center for Ethics in Science [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 071 Two new initiatives from the CSCC [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 072 A difference between normal and cancer SC biology in the nervous system [Last Updated On: January 7th, 2011] [Originally Added On: January 7th, 2011]
- 073 International Stem Cell Corporation Announces Company Update Conference Call [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 074 International Stem Cell Corporation Applauds Research Showing Parthenogenesis as a Potential Strategy for Treating Inherited Disease [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 075 International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells... [Last Updated On: January 26th, 2011] [Originally Added On: January 26th, 2011]
- 076 International Stem Cell Corporation: A Multitude Of Potential Products From Its Parthenogenesis Technology by Jason Chew [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 077 International Stem Cell Corporation Demonstrates Progress in the Use of Immune Matched Human Parthenogenetic Stem Cells to Promote the Development... [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 078 International Stem Cell Corporation: Note From The CEO Andrey Semechkin [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 079 "A Little Egg On the Face" - LifeLine Skin Care Stem Cell Cream Article [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 080 International Stem Cell Corporation Updates on 2010 Initial Product Launch of its Lifeline Skin Care Products [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
